Suppr超能文献

严重因子X缺乏症分娩时的血液制品支持:利用凝血酶生成指导治疗。

Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.

作者信息

van Veen Joost J, Hampton Kingsley K, Maclean Rhona, Fairlie Fiona, Makris Michael

机构信息

Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital,Sheffield, United Kingdom.

出版信息

Blood Transfus. 2007 Nov;5(4):204-9. doi: 10.2450/2007.0023-07.

Abstract

BACKGROUND

Severe FX deficiency is a rare disorder with a variable bleeding tendency but spontaneous life threatening haemorrhage can occur. Treatment for invasive procedures and spontaneous bleeding is with prothrombin complex concentrates (PCC). When used in large or repetitive doses these are associated with a thrombotic tendency. FX:C levels of 0.15 - 0.30 IU/ mL are thought to be haemostatic during surgery . There is only limited information on the outcome and management of pregnancy in severe FX deficiency. Caesarean section is suggested as delivery mode to reduce the risk of intracranial/abdominal neonatal haemorrhage, but successful vaginal deliveries are also described. The calibrated automated thrombin generation assay (CAT) is a global coagulation test that measures the time course of thrombin generation. It has been reported to correlate with prothrombotic states and the severity of bleeding in rare coagulation disorders. The variability in phenotype, the uncertainty of the minimal haemostatic FX:C concentration and the association of PCC's with thrombosis make thrombin generation of interest in the management of FX deficient patients.

PATIENT

We describe the use of CAT as a possible means to monitor treatment with PCC (Beriplex) in a patient with severe FX deficiency (FX:C < 0.01 IU/mL) during successful vaginal delivery and epidural anaesthesia.

RESULTS

Thrombin generation was normal at FX:C 0.80 IU/mL but only borderline normal at FX:C 0.25 IU/mL. Repetitive doses over 3 days increased thrombin generation to the upper limit of normal at FX:C 0.25 IU/mL consistent with a prothrombotic tendency after multiple doses. The increase in thrombin generation was not related to prothrombin levels.

CONCLUSION

The data suggest that CAT may be used to monitor treatment with PCC in FX deficiency. Higher levels than previously thought may be needed to normalize thrombin generation. Further studies into the correlation with bleeding or thrombosis are needed before the approach can be accepted in clinical practice.

摘要

背景

严重因子X(FX)缺乏症是一种罕见疾病,出血倾向各异,但可能发生危及生命的自发性出血。侵入性操作和自发性出血的治疗方法是使用凝血酶原复合物浓缩剂(PCC)。大剂量或重复使用这些药物会有血栓形成倾向。FX:C水平在0.15 - 0.30 IU/mL被认为在手术期间具有止血作用。关于严重FX缺乏症患者妊娠结局和管理的信息有限。建议剖宫产作为分娩方式以降低颅内/腹腔内新生儿出血风险,但也有成功阴道分娩的报道。校准自动凝血酶生成试验(CAT)是一种全面的凝血试验,可测量凝血酶生成的时间进程。据报道,它与血栓形成状态以及罕见凝血障碍中的出血严重程度相关。表型的变异性、最小止血FX:C浓度的不确定性以及PCC与血栓形成的关联使得凝血酶生成在FX缺乏症患者的管理中受到关注。

患者

我们描述了在一名严重FX缺乏症(FX:C < 0.01 IU/mL)患者成功阴道分娩和硬膜外麻醉期间,使用CAT作为监测PCC(贝赋)治疗的一种可能方法。

结果

FX:C为0.80 IU/mL时凝血酶生成正常,但FX:C为0.25 IU/mL时仅临界正常。3天内重复给药使FX:C为0.25 IU/mL时凝血酶生成增加至正常上限,这与多次给药后的血栓形成倾向一致。凝血酶生成的增加与凝血酶原水平无关。

结论

数据表明CAT可用于监测FX缺乏症患者的PCC治疗。可能需要比先前认为的更高水平才能使凝血酶生成正常化。在该方法被临床实践接受之前,需要进一步研究其与出血或血栓形成的相关性。

相似文献

2
Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency.
Haemophilia. 2021 Jul;27(4):531-543. doi: 10.1111/hae.14223. Epub 2021 May 22.
4
Clinical, Laboratory Aspects and Management of Factor X Deficiency.
Semin Thromb Hemost. 2025 Mar;51(2):138-144. doi: 10.1055/s-0044-1789595. Epub 2024 Aug 29.
5
Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro.
Br J Anaesth. 2018 Oct;121(4):936-943. doi: 10.1016/j.bja.2018.05.063. Epub 2018 Jul 4.
6
Fitusiran reduces bleeding in factor X-deficient mice.
Blood. 2024 Jul 11;144(2):227-236. doi: 10.1182/blood.2023023404.
7
Plasma-derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency.
Haemophilia. 2024 Jan;30(1):59-67. doi: 10.1111/hae.14894. Epub 2023 Oct 30.
10
Assessing the individual roles of FII, FV, and FX activity in the thrombin generation process.
Front Cardiovasc Med. 2022 Sep 20;9:1000812. doi: 10.3389/fcvm.2022.1000812. eCollection 2022.

引用本文的文献

1
Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding.
Cochrane Database Syst Rev. 2022 Nov 21;11(11):CD013551. doi: 10.1002/14651858.CD013551.pub2.
4
Rare coagulation disorders: an emerging issue.
Blood Transfus. 2007 Nov;5(4):185-6. doi: 10.2450/2007.0044-07.

本文引用的文献

3
Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3106-11. doi: 10.1073/pnas.0504240103. Epub 2006 Feb 17.
5
Thrombin generation and phenotypic correlation in haemophilia A.
Haemophilia. 2005 Jul;11(4):326-34. doi: 10.1111/j.1365-2516.2005.01107.x.
6
Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
Thromb Haemost. 2005 Mar;93(3):475-80. doi: 10.1160/TH04-10-0706.
7
Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition.
J Thromb Haemost. 2004 Nov;2(11):1954-9. doi: 10.1111/j.1538-7836.2004.00964.x.
8
Severe factor X deficiency in pregnancy: case report and review of the literature.
Haemophilia. 2004 Sep;10(5):665-8. doi: 10.1111/j.1365-2516.2004.01012.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验